Consequently, we investigated whether and to what degree a systematic review of symptoms in patients receiving biologic therapy for IBD, referred to as ‘STABILITY’, influenced levels of fecal calprotectin (FCP) [12,13], C-reactive protein (CRP), and erythrocyte sedimentation rate as standard clinical tests used to assess the severity of inflammation in IBD [14,15,16,17,18]. This evidence concerns the gene CRP and inflammatory bowel disease.